Plain-English translation of NCT04996797 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Ulcerative colitis research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial tested a medication called (also called MK-7240/PRA023) to see if it could help people with moderate to severe ulcerative colitis. About 178 people participated in this 12-week study, where some received the medication by IV infusion while others received a placebo. Researchers studied how safe the treatment was and whether it reduced symptoms of ulcerative colitis.
Ulcerative colitis is an inflammatory bowel condition that causes painful symptoms, and many people don't get relief from existing treatments. This trial was testing whether this new medication could offer hope to patients who had already tried other therapies without success.
Participants received IV infusions of either the new medication or a placebo at the start of the trial and at weeks 2, 6, and 10 over a 12-week period. The study was double-blinded, meaning neither participants nor researchers knew who was receiving the medication versus the placebo until the trial ended. After completing the 12-week phase, participants had the option to continue receiving open-label treatment (where everyone knows they're receiving the active medication) for up to 170 additional weeks to see longer-term effects.
AI-generated summary from trial data · Sep 21, 2026 · Not medical advice
United States